Voclosporin
Treatment for Lupus
Typical Dosage: 23.7 mg twice daily
Effectiveness
88%
Safety Score
35%
Clinical Trials
10
Participants
1.2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
23.7 mg twice daily
Time to Effect
3-6 months
Treatment Duration
1-2 years induction, then maintenance
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$90,000
Monitoring:$1,200
Side Effect Mgmt:$700
Total Annual:$91,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$255,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$204,222
Comparison vs Mycophenolate Mofetil + low-dose corticosteroids
Cost Difference
+$113,010/year
More expensive
QALY Difference
+0.44 QALYs
Better outcomes
Dominance
No dominance
Voclosporin Outcomes
for Lupus
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+45%
Common Side Effects
Hypertension
+40%
Kidney function impairment (elevated creatinine)
+25%
Headache
+25%
Increased infection risk
+15%
Active Clinical Trials
5 active trials recruiting for Voclosporin in Lupus
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
NCT07225387RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Glendale, United States +6 more
Started: Oct 1, 2024
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05962788ENROLLING BY INVITATIONPHASE3
40 participants
INTERVENTIONAL
Chapel Hill, United States +5 more
Started: Mar 27, 2024
LUPKYNIS Drug-use Results Survey
NCT07053891RECRUITING
400 participants
OBSERVATIONAL
Osaka, Japan
Started: Sep 17, 2025
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05288855RECRUITINGPHASE3
40 participants
INTERVENTIONAL
Orlando, United States +6 more
Started: Oct 10, 2023
A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis
NCT06406205RECRUITINGPHASE3
270 participants
INTERVENTIONAL
Bengbu, China +9 more
Started: Dec 25, 2023
Completed Clinical Trials
5 completed trials for Voclosporin in Lupus
Aurinia Early Urinary Protein Reduction Predicts Response
NCT02949973COMPLETEDPHASE2
10 participants
INTERVENTIONAL
Kuala Lumpur, Malaysia +1 more
Started: Jun 1, 2015
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
NCT02141672COMPLETEDPHASE2
265 participants
INTERVENTIONAL
Los Angeles, United States +85 more
Started: Jun 1, 2014
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
NCT05337124COMPLETED
229 participants
OBSERVATIONAL
South Gate, United States
Started: Apr 5, 2022
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
NCT03597464COMPLETEDPHASE3
216 participants
INTERVENTIONAL
Oklahoma City, United States
Started: Sep 29, 2019
Aurinia Renal Response in Active Lupus With Voclosporin
NCT03021499COMPLETEDPHASE3
358 participants
INTERVENTIONAL
Huntsville, United States +184 more
Started: May 17, 2017